A clinical-stage biotechnology company in Immuno-Oncology and Immuno-Inflammation

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more


OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update

Dominique Costantini
founder and chairwoman

OSE Immunotherapeutics celebrates its 10th anniversary!

The founder and chairwoman, Dominique Costantini, shares the company's purpose: "We have a passion for innovation and develop first-in-class immunotherapies". Discover in this video, the short- and medium-term objectives of OSE Immunotherapeutics for 2023.
Nicolas Poirier

OSE Immunotherapeutics celebrates its 10th anniversary!

Nicolas Poirier, CEO, presents the product portfolio with a focus on most advanced clinical programmes: "We have developed a rich and diversified product portfolio, with a strategy based on the development of assets in-house to create more value and on strategic quality partnerships".

To receive OSE Immunotherapeutics’ latest news